Bayer Loses Nexavar Compulsory License Appeal; Next Stop: Mumbai High Court
This article was originally published in PharmAsia News
Executive Summary
A keenly watched court tussle over a compulsory license for Nexavar reached a critical point, and while Bayer lost this round, the battle isn’t over yet.